Place · Level 3 · Condition
Osteoporosis
DXA T + FRAX · 髋骨折 1 年死亡 20-30% · 钙+D+蛋白+力量 · 双膦/Denos/Romo · 围绝经窗口
Last updated
Story path
Chapter 1
The silent killer
The silent killer
Osteoporosis = progressive decline in bone mineral density and microarchitecture → ↑ risk of fragility fracture.
Epidemiology (China Osteoporosis Prevalence Study, 2017-2018 fieldwork, n=20,416 — Wang 2021):
Aged 40+: 20.6% of women and 5.0% of men have osteoporosisVertebral fracture in the same 40+ population: 10.5% of men and 9.7% of women — nearly identical between the sexes, which is not what most people expectOnly 1.4% of women and 0.3% of men with osteoporosis or a fracture were receiving treatment~ 2 million fragility fractures per yearHip-fracture 1-year mortality 20-30%, residual disability 40-50%One of the leading causes of disability in older adults
WHO osteoporosis definition (DXA T-score):
Normal: T ≥ -1.0Osteopenia: -2.5 < T < -1.0Osteoporosis: T ≤ -2.5Severe osteoporosis: T ≤ -2.5 + any fragility fracture
DXA:
Lumbar spine + hip + femoral neck standard sitesScreening: women 65+, men 70+ (any) / 60+ (with risk)
Risk factors:
Non-modifiable: female + older age + family history + early menopause + Caucasian / Asian + small frameModifiable:Insufficient calcium / D / protein intakeSedentary lifestyleSmoking + heavy alcoholLow body weight (BMI < 18.5)Long-term steroids (≥ 5 mg prednisone-equivalent ≥ 3 months)Hypogonadism (low T / low E2)Hyperthyroidism / hyperparathyroidism / Cushing'sEstrogen blockers (aromatase inhibitors for breast cancer)Long-term PPI / anticonvulsants / SSRI / chemotherapy
FRAX assessment (Kanis 2008):
10-year major + hip-fracture probabilityIntegrates age / sex / BMI / risk factors / DXAOnline tool: FRAX.shef.ac.uk (China model available)DXA + FRAX combined drives treatment
Common osteoporotic fracture sites:
Vertebral compression (most common, 50%+ of patients): sudden back pain; some asymptomatic and only found on X-ray → height loss + kyphosisHip fractures (femoral neck / intertrochanteric): the most serious in older adultsDistal radius (Colles' fracture): from a fall onto an outstretched hand; common first presentation in middle-aged womenProximal humerus / ribs / pelvis: other fragility sites
"The postmenopausal window" (atlas perimenopause L4):
Bone loss is fastest in the first 5-10 years post-menopause (-2-5%/year)Building reserve at 35-50 + early intervention at menopause = the key to lifelong bone health
Epidemiology (China Osteoporosis Prevalence Study, 2017-2018 fieldwork, n=20,416 — Wang 2021):
Aged 40+: 20.6% of women and 5.0% of men have osteoporosisVertebral fracture in the same 40+ population: 10.5% of men and 9.7% of women — nearly identical between the sexes, which is not what most people expectOnly 1.4% of women and 0.3% of men with osteoporosis or a fracture were receiving treatment~ 2 million fragility fractures per yearHip-fracture 1-year mortality 20-30%, residual disability 40-50%One of the leading causes of disability in older adults
WHO osteoporosis definition (DXA T-score):
Normal: T ≥ -1.0Osteopenia: -2.5 < T < -1.0Osteoporosis: T ≤ -2.5Severe osteoporosis: T ≤ -2.5 + any fragility fracture
DXA:
Lumbar spine + hip + femoral neck standard sitesScreening: women 65+, men 70+ (any) / 60+ (with risk)
Risk factors:
Non-modifiable: female + older age + family history + early menopause + Caucasian / Asian + small frameModifiable:Insufficient calcium / D / protein intakeSedentary lifestyleSmoking + heavy alcoholLow body weight (BMI < 18.5)Long-term steroids (≥ 5 mg prednisone-equivalent ≥ 3 months)Hypogonadism (low T / low E2)Hyperthyroidism / hyperparathyroidism / Cushing'sEstrogen blockers (aromatase inhibitors for breast cancer)Long-term PPI / anticonvulsants / SSRI / chemotherapy
FRAX assessment (Kanis 2008):
10-year major + hip-fracture probabilityIntegrates age / sex / BMI / risk factors / DXAOnline tool: FRAX.shef.ac.uk (China model available)DXA + FRAX combined drives treatment
Common osteoporotic fracture sites:
Vertebral compression (most common, 50%+ of patients): sudden back pain; some asymptomatic and only found on X-ray → height loss + kyphosisHip fractures (femoral neck / intertrochanteric): the most serious in older adultsDistal radius (Colles' fracture): from a fall onto an outstretched hand; common first presentation in middle-aged womenProximal humerus / ribs / pelvis: other fragility sites
"The postmenopausal window" (atlas perimenopause L4):
Bone loss is fastest in the first 5-10 years post-menopause (-2-5%/year)Building reserve at 35-50 + early intervention at menopause = the key to lifelong bone health
断在哪里 · 谁风险高 · 怎么确诊
骨头最容易断的几个地方, 认得出来也有用:脊椎压缩: 最常见的一种。有的是突然腰背痛, 有的悄无声息, 拍片才发现——时间久了会变矮加驼背。髋部 (股骨颈那一带): 老人最凶险的一处。手腕: 跌倒时手一撑就容易折, 常是中年女性第一次发现问题的地方。
哪些人风险更高? 有些改不了: 女性、上了年纪、家里有人得过、绝经早、身材瘦小。但更多是能改的: 钙、维生素 D、蛋白质吃得不够, 不运动, 抽烟, 大量喝酒, 体重过低, 以及长期吃类固醇激素。后面几幕会一件件讲怎么补。
医生怎么判断? 主要靠一次骨密度扫描 (DXA), 它给你一个叫 T 值的分数, 低到 T ≤ -2.5 就算骨质疏松; 再配一个叫 FRAX 的在线工具, 估算你未来 10 年的骨折风险。这两样具体怎么读、到哪条线该考虑吃药, 下一页细讲。
FRAX practical + treatment tree
FRAX is not a single number — it is a decision tool. Yet many clinicians and patients don't know how to use it. Here is the practical breakdown.FRAX inputs (online tool frax.shef.ac.uk, 14 items):
Age (40-90)SexWeight + height (computes BMI)Prior fracture (Y/N)Parental hip fracture (Y/N)Current smoking (Y/N)Steroid use (≥ 5 mg/day prednisone ≥ 3 months)Rheumatoid arthritis (Y/N)Secondary osteoporosis (T1DM / hypogonadism / hyperparathyroidism / early menopause, etc., Y/N)Heavy alcohol (≥ 3 units/day, Y/N)Femoral-neck DXA T-score (optional, improves accuracy)
Outputs:
10-year major osteoporotic fracture (MOF) probability, % — includes hip / vertebra / humerus / wrist10-year hip-fracture probability, %
Treatment thresholds (NOF 2014 / AACE 2020):
Absolute indications (treat immediately, no need to compute FRAX):
DXA T ≤ -2.5 (any site: lumbar / total hip / femoral neck)Any fragility fracture (vertebra / hip / wrist / humerus) — even if T is in the osteopenia range
FRAX decision (T between -1.0 and -2.5, osteopenia):
10-year hip fracture ≥ 3% OR10-year major fracture ≥ 20%→ treat pharmacologicallyBelow → lifestyle + nutrition + strength training; no drug needed
Country calibration:
FRAX has 80+ country calibrations (China-male / China-female + separate Hong Kong + Taiwan models)Mainland China calibration is based on a 2003 cohort and may underestimate current risk (population ageing)Some clinicians use the Hong Kong calibration + DXA T < -2.5 dual criteria
FRAX limitations:
Does not include fall frequency + balance + visionDoes not include trabecular bone score (TBS)Does not include vertebral morphology / microfracturesDoes not include some secondary causes (CKD, steroid-dose gradient)Clinical judgment beyond FRAX: repeated falls / very strong family history / abnormal spine imaging → treat even with low FRAX
Practical decision tree:
```
┌─ Any fragility fracture (vertebra/hip/wrist/humerus) → treat immediately (T-score irrelevant)
│
├─ DXA T ≤ -2.5 → treat immediately
│
├─ DXA T between -1.0 and -2.5 (osteopenia) → compute FRAX:
│ ├─ Hip ≥ 3% or MOF ≥ 20% → treat
│ └─ Below → nutrition + exercise, repeat DXA every 2 years
│
└─ DXA T > -1.0 → nutrition + exercise + prevention, repeat every 3-5 years
```
"Should I do DXA?":
Women ≥ 65 + men ≥ 70: routine screeningWomen < 65 / men < 70: only with ≥ 1 major risk factor (early menopause / steroids / family history of fragility fracture / BMI < 18.5 / smoking)Don't do it casually — universal screening of asymptomatic young people is pointless
kanis-2008-frax
Chapter 2
RANKL/OPG + bisphos
RANKL/OPG + bisphos
Bone is not stone — it is a living tissue continually being torn down and rebuilt.
Two key cell types:
Osteoblasts: secrete osteoid + osteocalcin → mineralisation → build boneOsteoclasts: large multinucleated cells secreting acid + cathepsin K → digest bone matrix → tear bone down
Key insight (Simonet 1997 + Hofbauer 1999 classics): osteoblasts also secrete:
RANKL (Receptor Activator of nuclear factor kappa B: The cell's inflammation master switch (a transcription factor) — when flipped, it turns inflammation on. Ligand) → activates osteoclast precursors → resorptionOPG (Osteoprotegerin) → a "decoy receptor" binding RANKL → prevents it binding RANK → bone preservation
receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone. / OPG ratio → determines net resorption rate:
RANKL ≫ OPG → bone lossOPG ≫ RANKL → preservation / accretion
Regulators:
↑ RANKL (pro-resorption): chronic parathyroid hormone: Released when blood calcium dips — it pulls calcium back into the blood from bone, kidney, and gut. / steroids / TNFα + IL-1 / interleukin-6: A pro-inflammatory signal molecule (cytokine) released by immune cells during inflammation. / postmenopausal estrogen loss → rapid bone loss in the first 5-10 years
↑ OPG (pro-preservation): mechanical loading (strength + high-impact) / estrogen / vitamin D / K2 / adequate protein / anti-inflammatory diet
Chemistry of the postmenopausal window:
In year 1 of menopause, estrogen plummets → RANKL ↑ + OPG ↓ → ratio rises 2-3 ×Fastest bone loss in the first 5-10 years (-2-5%/year)Not "wait until DXA at 65" — but "intervene starting year 1 of menopause"
Osteoclast resorption chemistry (acid pit):
Attaches to bone surface → forms a ruffled-border sealed compartmentV-ATPase + CLC-7 → pump H⁺ → pH 4.5Hydroxyapatite dissolves in acid → Ca²⁺ + PO₄³⁻ releasedCathepsin K + MMP-9 → digest collagen
Bisphosphonate 4-step mechanism:
1. Deposit on bone surface: P-C-P backbone has extreme affinity for hydroxyapatite; half-life of years to over a decade
2. Silent dormancy: no effect when osteoclasts are inactive
3. Osteoclast ingestion: while resorbing the bone surface, the cell "mistakenly ingests" drug-containing HA; the acid pit at pH 4.5 releases it intracellularly
4. Apoptosis at 48-72 h: nitrogen bisphosphonates inhibit FPPS → small GTPases fail to undergo prenylation → cytoskeleton collapse
Clinical results:
Black 2007 NEJM HORIZON (zoledronic acid 5 mg/year IV): vertebral fractures ↓ 70%, hip fractures ↓ 41%Cummings 2009 NEJM FREEDOM (denosumab 60 mg/6 months): vertebral ↓ 68%, hip ↓ 40%
Denosumab rebound warning:
Stopping → 6-12 months later, RANKL signalling returns + risk of multiple vertebral fracturesMust bridge with one IV zoledronate dose — never simply discontinue
Drugs ≠ the final answer:
Build reserve at 35-50: nutrition + strength training + appropriate body weightEarly menopausal intervention: HRT evaluation (atlas perimenopause/mht L4) + strength + Ca + D + K2No drug fully substitutes for the mechanical stimulus of strength training
Atlas connections: osteoporosis + bone/hormones + calcium/blood + calcium/bone-deposit + vitamin-d + vitamin-k2 + protein/muscle + sarcopenia + perimenopause/mht + andropause.
Two key cell types:
Osteoblasts: secrete osteoid + osteocalcin → mineralisation → build boneOsteoclasts: large multinucleated cells secreting acid + cathepsin K → digest bone matrix → tear bone down
Key insight (Simonet 1997 + Hofbauer 1999 classics): osteoblasts also secrete:
RANKL (Receptor Activator of nuclear factor kappa B: The cell's inflammation master switch (a transcription factor) — when flipped, it turns inflammation on. Ligand) → activates osteoclast precursors → resorptionOPG (Osteoprotegerin) → a "decoy receptor" binding RANKL → prevents it binding RANK → bone preservation
receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone. / OPG ratio → determines net resorption rate:
RANKL ≫ OPG → bone lossOPG ≫ RANKL → preservation / accretion
Regulators:
↑ RANKL (pro-resorption): chronic parathyroid hormone: Released when blood calcium dips — it pulls calcium back into the blood from bone, kidney, and gut. / steroids / TNFα + IL-1 / interleukin-6: A pro-inflammatory signal molecule (cytokine) released by immune cells during inflammation. / postmenopausal estrogen loss → rapid bone loss in the first 5-10 years
↑ OPG (pro-preservation): mechanical loading (strength + high-impact) / estrogen / vitamin D / K2 / adequate protein / anti-inflammatory diet
Chemistry of the postmenopausal window:
In year 1 of menopause, estrogen plummets → RANKL ↑ + OPG ↓ → ratio rises 2-3 ×Fastest bone loss in the first 5-10 years (-2-5%/year)Not "wait until DXA at 65" — but "intervene starting year 1 of menopause"
Osteoclast resorption chemistry (acid pit):
Attaches to bone surface → forms a ruffled-border sealed compartmentV-ATPase + CLC-7 → pump H⁺ → pH 4.5Hydroxyapatite dissolves in acid → Ca²⁺ + PO₄³⁻ releasedCathepsin K + MMP-9 → digest collagen
Bisphosphonate 4-step mechanism:
1. Deposit on bone surface: P-C-P backbone has extreme affinity for hydroxyapatite; half-life of years to over a decade
2. Silent dormancy: no effect when osteoclasts are inactive
3. Osteoclast ingestion: while resorbing the bone surface, the cell "mistakenly ingests" drug-containing HA; the acid pit at pH 4.5 releases it intracellularly
4. Apoptosis at 48-72 h: nitrogen bisphosphonates inhibit FPPS → small GTPases fail to undergo prenylation → cytoskeleton collapse
Clinical results:
Black 2007 NEJM HORIZON (zoledronic acid 5 mg/year IV): vertebral fractures ↓ 70%, hip fractures ↓ 41%Cummings 2009 NEJM FREEDOM (denosumab 60 mg/6 months): vertebral ↓ 68%, hip ↓ 40%
Denosumab rebound warning:
Stopping → 6-12 months later, RANKL signalling returns + risk of multiple vertebral fracturesMust bridge with one IV zoledronate dose — never simply discontinue
Drugs ≠ the final answer:
Build reserve at 35-50: nutrition + strength training + appropriate body weightEarly menopausal intervention: HRT evaluation (atlas perimenopause/mht L4) + strength + Ca + D + K2No drug fully substitutes for the mechanical stimulus of strength training
Atlas connections: osteoporosis + bone/hormones + calcium/blood + calcium/bone-deposit + vitamin-d + vitamin-k2 + protein/muscle + sarcopenia + perimenopause/mht + andropause.
绝经那扇窗 · 破骨细胞的酸坑
这正好说清了绝经后那个窗口为什么这么凶: 绝经头一年雌激素骤降, receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone. 冒上来、OPG 掉下去, 两者的比值一下子拉高到 2-3 倍, 头 5-10 年骨头流失最快 (每年约 -2 至 -5%)。所以最该动手的时机, 不是等 65 岁做完骨密度再说, 而是绝经的头一年就开始。再凑近看一眼破骨细胞到底怎么拆骨: 它像吸盘一样贴住骨面, 围出一个密封的小坑, 往里灌酸, 把坑里的酸度打到 pH 4.5——骨头里的钙盐 (羟基磷灰石) 在这么强的酸里会溶掉, 钙和磷被释放出来, 剩下的胶原再由专门的酶消化掉。记住这个酸坑, 下一页的药正是钻它的空子。
双膦酸盐: 将计就计的四步
双膦酸盐 (bisphosphonates) 这类经典药, 走的是一套将计就计的四步:1. 先埋伏在骨面: 它对骨头钙盐的亲和力极强, 一旦贴上去能待好几年、甚至十几年。
2. 按兵不动: 只要那块骨面没有破骨细胞来拆, 它就静静躺着, 不起作用。
3. 等着被吃进去: 破骨细胞一来拆这块骨, 就会连药一起吞下肚, 酸坑一溶, 药便进了破骨细胞体内。
4. 让拆骨工自毁: 药在细胞里打断一条关键的加工流水线, 让破骨细胞的骨架撑不住, 大约 48-72 小时后自行凋亡——拆骨的队伍就被精准地削下去。
效果有硬数据撑着: 唑来膦酸 (每年一针 5 mg 静脉滴注, Black 2007 NEJM HORIZON) 把脊椎骨折降了 70%、髋骨折降了 41%; 抗 receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone. 的狄诺塞麦 (denosumab, 每半年一针 60 mg, Cummings 2009 NEJM FREEDOM) 把脊椎骨折降了 68%、髋骨折降了 40%。
停药会反弹 · 药不是终点
狄诺塞麦有个必须记住的反弹陷阱: 一旦停药, 6-12 个月内被压住的 receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone. 信号会猛地反扑回来, 可能一下子摔出好几处脊椎骨折。所以它不能说停就停, 通常要用一针双膦酸盐来接棒过渡。最后别忘了: 药不是终点。35-50 岁靠营养、力量训练和合理体重先把骨本打厚; 绝经时尽早评估激素替代 (atlas perimenopause/mht L4)、再加上力量训练和钙、D、K2——没有任何一种药能替代力量训练给骨头的那份机械刺激。
相连的话题: osteoporosis + bone/hormones + calcium/blood + calcium/bone-deposit + vitamin-d + vitamin-k2 + protein/muscle + sarcopenia + perimenopause/mht + andropause.
Chapter 3
Nutrition + exercise
Nutrition + exercise
First-line non-pharmacologic interventions for osteoporosis:
① Calcium:
Women 50+ y/o 1200 mg/day / men 1000-1200 mgFood first: milk / yogurt / cheese / dark leafy greens / calcium-set tofu / small whole fish / fortified foodsNo need to exceed 1200 mg — the Bolland 2015 fracture review found calcium supplements cut total fracture by only about 11%. As for the older calcium-hurts-the-heart dispute: it came from Bolland 2010, and the 2016 NOF/ASPC review concluded calcium within the UL is cardiovascular-neutral, whether from food or pillsSupplements: with meals + split doses (≤ 500 mg per dose for best absorption)See atlas calcium
② Vitamin D:
50+ y/o 800-1000 IU/day, more if deficient25-hydroxyvitamin D: The storage form of vitamin D in blood — the number measured to check D status. target 30-50 ng/mL (75-125 nmol/L)Combine food + sun + supplementsMultiple L4s on atlas vitamin-d
③ Protein:
1.0-1.2 g/kg/day (healthy elderly) / 1.2-1.5 g/kg/day (fracture recovery / chronic disease)25-40 g per meal + 2.5 g leucine to trigger MPS (atlas protein/muscle L4)"Elderly should eat less protein" is a wrong cultural expectation (atlas sarcopenia)
④ Vitamin K2:
MGP + osteocalcin γ-carboxylation (atlas vitamin-k2/bone L4)Rotterdam cohort: high K2 intake → ↓ CHD 57% + ↓ aortic calcification 52%MK-7 90-180 µg/day + MK-4 45 mg/day (higher dose)Food: natto (the MK-7 king) / certain hard cheeses (MK-4)
⑤ Magnesium + zinc + B12 + folate:
Comprehensive bone-health nutrients; supplement if deficientMg 320-420 mg/day (elemental)See atlas magnesium / zinc / b12 / folate
⑥ Strength training (strongest non-pharmacologic intervention):
Mechanical loading → osteoblast activation → ↑ BMD2-3 sessions/week, focus on hip + spine + wrist (fracture-prone sites)Jumping + high-impact: bone is built by being struck, not by being walked on. The cleanest measurement is in children — 100 jumps off a 61 cm box, 3×/week for 7 months, gave a 4.5% greater gain in femoral-neck bone mineral content than controls (Fuchs 2001, in 89 prepubescent children). The adult effect size is much smaller, but the direction holds: impact + resistance beat aerobic workResistance training: barbell squat / deadlift / dumbbell press / row70+ y/o: modified low-impact strength training (atlas sarcopenia)Important: walking / strolling has limited effect on BMD (insufficient mechanical load)
⑦ Fall prevention:
Balance training (tai chi / single-leg stance): pooling every exercise trial, the fall rate in older adults fell 21%; programmes that both challenged balance and ran more than 3 h/week got to 39% (Sherrington 2017, 88 trials / 19,478 people). The dose is half the finding — tai chi qualifies as balance-challenging, but only if you do enough of itHome safety: anti-slip mats + handrails + adequate lightingVision correction + hearing check + foot health + avoid sedativesStrength training + balance training + fall prevention = the elderly bone-health triad
⑧ Quit smoking + limit alcohol:
Smoking → ↓ estrogen + directly suppresses osteoblastsAlcohol > 30 g/day → ↓ bone formation + ↑ fall risk
⑨ Long-term PPI / steroids:
Long-term PPI → ↓ Ca/Mg absorption → ↑ fracture risk (atlas conditions/GERD)Long-term steroids → rapidly accelerated osteoporotic fracturesDiscuss dose / duration with the clinician + intensify calcium + D
① Calcium:
Women 50+ y/o 1200 mg/day / men 1000-1200 mgFood first: milk / yogurt / cheese / dark leafy greens / calcium-set tofu / small whole fish / fortified foodsNo need to exceed 1200 mg — the Bolland 2015 fracture review found calcium supplements cut total fracture by only about 11%. As for the older calcium-hurts-the-heart dispute: it came from Bolland 2010, and the 2016 NOF/ASPC review concluded calcium within the UL is cardiovascular-neutral, whether from food or pillsSupplements: with meals + split doses (≤ 500 mg per dose for best absorption)See atlas calcium
② Vitamin D:
50+ y/o 800-1000 IU/day, more if deficient25-hydroxyvitamin D: The storage form of vitamin D in blood — the number measured to check D status. target 30-50 ng/mL (75-125 nmol/L)Combine food + sun + supplementsMultiple L4s on atlas vitamin-d
③ Protein:
1.0-1.2 g/kg/day (healthy elderly) / 1.2-1.5 g/kg/day (fracture recovery / chronic disease)25-40 g per meal + 2.5 g leucine to trigger MPS (atlas protein/muscle L4)"Elderly should eat less protein" is a wrong cultural expectation (atlas sarcopenia)
④ Vitamin K2:
MGP + osteocalcin γ-carboxylation (atlas vitamin-k2/bone L4)Rotterdam cohort: high K2 intake → ↓ CHD 57% + ↓ aortic calcification 52%MK-7 90-180 µg/day + MK-4 45 mg/day (higher dose)Food: natto (the MK-7 king) / certain hard cheeses (MK-4)
⑤ Magnesium + zinc + B12 + folate:
Comprehensive bone-health nutrients; supplement if deficientMg 320-420 mg/day (elemental)See atlas magnesium / zinc / b12 / folate
⑥ Strength training (strongest non-pharmacologic intervention):
Mechanical loading → osteoblast activation → ↑ BMD2-3 sessions/week, focus on hip + spine + wrist (fracture-prone sites)Jumping + high-impact: bone is built by being struck, not by being walked on. The cleanest measurement is in children — 100 jumps off a 61 cm box, 3×/week for 7 months, gave a 4.5% greater gain in femoral-neck bone mineral content than controls (Fuchs 2001, in 89 prepubescent children). The adult effect size is much smaller, but the direction holds: impact + resistance beat aerobic workResistance training: barbell squat / deadlift / dumbbell press / row70+ y/o: modified low-impact strength training (atlas sarcopenia)Important: walking / strolling has limited effect on BMD (insufficient mechanical load)
⑦ Fall prevention:
Balance training (tai chi / single-leg stance): pooling every exercise trial, the fall rate in older adults fell 21%; programmes that both challenged balance and ran more than 3 h/week got to 39% (Sherrington 2017, 88 trials / 19,478 people). The dose is half the finding — tai chi qualifies as balance-challenging, but only if you do enough of itHome safety: anti-slip mats + handrails + adequate lightingVision correction + hearing check + foot health + avoid sedativesStrength training + balance training + fall prevention = the elderly bone-health triad
⑧ Quit smoking + limit alcohol:
Smoking → ↓ estrogen + directly suppresses osteoblastsAlcohol > 30 g/day → ↓ bone formation + ↑ fall risk
⑨ Long-term PPI / steroids:
Long-term PPI → ↓ Ca/Mg absorption → ↑ fracture risk (atlas conditions/GERD)Long-term steroids → rapidly accelerated osteoporotic fracturesDiscuss dose / duration with the clinician + intensify calcium + D
各吃多少 · 钙 / D / 蛋白
钙: 50 岁以后, 女性一天大约 1200 mg、男性 1000-1200 mg, 首选从食物里拿。真要额外补, 记两点: 一次别超过 500 mg (分几次吃吸收更好)、随餐服用; 也不必猛补到超过 1200 mg —— 补过头并不会更护骨 (Bolland 2015 那篇 BMJ 系统综述里, 钙补剂对总骨折的降幅只有约 11%)。至于补钙伤心脏那桩旧公案: 提出它的是 Bolland 2010 那篇 meta, 而 2016 年 NOF 与 ASPC 复核后的共识是 —— 可耐受最高摄入量以内的钙, 无论来自食物还是补剂, 对心血管都是中性的。食物优先仍然值得坚持, 但理由是整体营养, 不是心血管风险。维生素 D: 50 岁以上一般 800-1000 IU/天, 缺得多的还要加, 目标是把血里的 25-hydroxyvitamin D: The storage form of vitamin D in blood — the number measured to check D status. 拉到 30-50 ng/mL。晒太阳、吃、补三条路一起走。
蛋白质: 健康老人每天按体重 1.0-1.2 g/kg, 正在养骨折或有慢病的要到 1.2-1.5 g/kg; 而且最好每顿都摊上 25-40 g 蛋白, 才够劲儿把肌肉的合成开关打开。
练多少 · 怎么不摔
力量训练一周 2-3 次, 抗阻和冲击都要有 —— 骨头是被砸出来的, 不是被走出来的。这件事在孩子身上量得最干净: 每周 3 次、每次从 61 cm 高台往下跳 100 次, 7 个月后股骨颈的骨矿含量比对照组多涨 4.5% (Fuchs 2001, 89 名学龄前后的儿童)。成年人身上的量级要小得多, 但方向一致。上了 70 岁也别停, 换成低冲击的改良版接着练。防跌倒和练力量一样要紧, 但剂量决定收益: 把所有运动干预汇总起来, 老人的跌倒率降约 21%; 而既挑战平衡、每周又练满 3 小时以上的方案能降到 39% (Sherrington 2017, 88 项试验 / 19,478 人)。太极、单腿站正是挑战平衡的那一半 —— 另一半是练够时间。家里再做点防滑、扶手、够亮的照明, 配好眼镜、查查听力、少吃让人发晕的镇静药。力量 + 平衡 + 防跌倒, 是老年骨健康的三件套。
锦上添花的营养 · 要避开的坑
剩下几样是锦上添花, 缺了才补、不用堆: 维生素 K2 帮钙老老实实待在骨头里、别乱跑去血管壁上 (纳豆里最多, 常见剂量 MK-7 90-180 µg/天); 镁 (约 320-420 mg/天)、锌、B12、叶酸也都参与造骨, 平时吃杂一点基本就够。最后是两个要主动避开的坑: 烟和酒——抽烟压低雌激素、直接拖累造骨, 每天酒精超过 30 g 既减少骨形成又增加跌倒; 有些长期吃的药也伤骨, 比如抑酸的 PPI (影响钙、镁吸收) 和类固醇激素 (掉骨特别快)——别自己乱停, 但要和医生商量剂量和时长, 同时加强补钙和维 D。
Chapter 4
Male OP + secondary causes
Male OP + secondary causes
Male osteoporosis + secondary osteoporosis are seriously underestimated. This scene treats them separately because they affect 1/3 of fracture patients and have an even higher rate of clinical neglect.
Male osteoporosis:
Epidemiology:
50+ y/o men have ~ 1/4 lifetime fracture risk (vs ~ 1/2 in women)1-year hip-fracture mortality 30-40% in men, higher than women (more comorbidities + later presentation)DXA screening rate in men < 20% (vs ~ 50% in women) — a huge clinical gap
How male osteoporosis differs:
More secondary causes (~ 60% in men vs ~ 30% in women) — must work upLater symptomatic onset (higher peak BMD + no abrupt menopausal drop)Often dismissed as "men don't get osteoporosis" → missed diagnoses
Male secondary causes — mandatory panel:
Hypogonadism (low T): most common reversible cause. Total T + SHBG + bioavailable T (atlas andropause L4)Hyperthyroidism / hypothyroidismPrimary hyperparathyroidism (HPT): parathyroid hormone: Released when blood calcium dips — it pulls calcium back into the blood from bone, kidney, and gut. + Ca + PCushing's syndrome: 24-h urinary cortisol / dexamethasone suppressionLong-term glucocorticoid use (≥ 5 mg prednisone-equivalent ≥ 3 months): the most common iatrogenic causeExcess alcohol (≥ 3 drinks/day): direct osteoblast suppression + fallsSmokingVitamin D deficiency (25-hydroxyvitamin D: The storage form of vitamin D in blood — the number measured to check D status. < 20 ng/mL)Chronic kidney disease (CKD 3-5): CKD-MBD syndromeMultiple myeloma: 50+ y/o + unexplained bone pain / pathological fracture → SPEP + UPEP + free light chainsCeliac diseaseHIV + antiretroviral therapyAnti-androgen therapy (ADT for prostate cancer): huge risk, requires anti-osteoporotic co-therapyAntiepileptics (phenytoin / carbamazepine): accelerate vitamin D metabolism
Male DXA screening timing (Endocrine Society 2012):
All men 70+50-69 with risk factors: any fragility fracture / steroids / hypogonadism / low body weight / smoking / heavy alcohol / androgen deprivation / long-term PPI / antiepileptics
Secondary osteoporosis lab panel (both sexes):
Baseline: CBC + creatinine + Ca + P + 25(OH)D + PTH + thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. + 24-h urinary calcium + LFTsMen: + total T + SHBGWomen with early menopause: + FSH + E2Suspected specific causes: SPEP / UPEP + free light chains (myeloma) / 24-h urinary cortisol (Cushing's) / anti-tissue transglutaminase IgA (celiac)
Treatment adjustments by specific secondary cause:
Glucocorticoid-induced osteoporosis (GIOP): start bisphosphonates immediately (even with T > -1.5) + Ca + D; do not delayMale low T + osteoporosis: TRT evaluation (atlas andropause/trt L4); do not prescribe TRT for borderline symptomsHyperparathyroidism: surgical adenoma removal; osteoporosis often reversesCKD-MBD: cannot use standard bisphosphonates (contraindicated when eGFR < 30); use denosumab (dose-adjusted) or conservative careCeliac: gluten-free diet + nutritional repletion; BMD reverses over 1-2 years
"Men don't get osteoporosis" must be broken:
Men have worse post-fracture survival (comorbidities)Male socialisation against seeking care → "I can't have osteoporosis" → second-fracture window missedAny fragility fracture in a man = immediate DXA + secondary work-upDon't postpone just because "he can still walk"
Male osteoporosis:
Epidemiology:
50+ y/o men have ~ 1/4 lifetime fracture risk (vs ~ 1/2 in women)1-year hip-fracture mortality 30-40% in men, higher than women (more comorbidities + later presentation)DXA screening rate in men < 20% (vs ~ 50% in women) — a huge clinical gap
How male osteoporosis differs:
More secondary causes (~ 60% in men vs ~ 30% in women) — must work upLater symptomatic onset (higher peak BMD + no abrupt menopausal drop)Often dismissed as "men don't get osteoporosis" → missed diagnoses
Male secondary causes — mandatory panel:
Hypogonadism (low T): most common reversible cause. Total T + SHBG + bioavailable T (atlas andropause L4)Hyperthyroidism / hypothyroidismPrimary hyperparathyroidism (HPT): parathyroid hormone: Released when blood calcium dips — it pulls calcium back into the blood from bone, kidney, and gut. + Ca + PCushing's syndrome: 24-h urinary cortisol / dexamethasone suppressionLong-term glucocorticoid use (≥ 5 mg prednisone-equivalent ≥ 3 months): the most common iatrogenic causeExcess alcohol (≥ 3 drinks/day): direct osteoblast suppression + fallsSmokingVitamin D deficiency (25-hydroxyvitamin D: The storage form of vitamin D in blood — the number measured to check D status. < 20 ng/mL)Chronic kidney disease (CKD 3-5): CKD-MBD syndromeMultiple myeloma: 50+ y/o + unexplained bone pain / pathological fracture → SPEP + UPEP + free light chainsCeliac diseaseHIV + antiretroviral therapyAnti-androgen therapy (ADT for prostate cancer): huge risk, requires anti-osteoporotic co-therapyAntiepileptics (phenytoin / carbamazepine): accelerate vitamin D metabolism
Male DXA screening timing (Endocrine Society 2012):
All men 70+50-69 with risk factors: any fragility fracture / steroids / hypogonadism / low body weight / smoking / heavy alcohol / androgen deprivation / long-term PPI / antiepileptics
Secondary osteoporosis lab panel (both sexes):
Baseline: CBC + creatinine + Ca + P + 25(OH)D + PTH + thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. + 24-h urinary calcium + LFTsMen: + total T + SHBGWomen with early menopause: + FSH + E2Suspected specific causes: SPEP / UPEP + free light chains (myeloma) / 24-h urinary cortisol (Cushing's) / anti-tissue transglutaminase IgA (celiac)
Treatment adjustments by specific secondary cause:
Glucocorticoid-induced osteoporosis (GIOP): start bisphosphonates immediately (even with T > -1.5) + Ca + D; do not delayMale low T + osteoporosis: TRT evaluation (atlas andropause/trt L4); do not prescribe TRT for borderline symptomsHyperparathyroidism: surgical adenoma removal; osteoporosis often reversesCKD-MBD: cannot use standard bisphosphonates (contraindicated when eGFR < 30); use denosumab (dose-adjusted) or conservative careCeliac: gluten-free diet + nutritional repletion; BMD reverses over 1-2 years
"Men don't get osteoporosis" must be broken:
Men have worse post-fracture survival (comorbidities)Male socialisation against seeking care → "I can't have osteoporosis" → second-fracture window missedAny fragility fracture in a man = immediate DXA + secondary work-upDon't postpone just because "he can still walk"
继发性原因: 该过一遍的清单
不少骨质疏松是别的病或药顺带造成的, 在男性里这种继发原因占到约 60% (女性约 30%), 比女性高不少; 找出来往往能对因处理、甚至逆转。常见的几类, 心里有个数:激素方面: 男性睾酮偏低是最常见、也最可逆的一个原因; 甲状腺功能亢进、甲状旁腺功能亢进、库欣综合征这些内分泌问题也会悄悄掉骨。药物方面: 长期吃类固醇激素 (每天相当于 5 mg 强的松、连吃 3 个月以上) 是头号的医源性原因; 抑酸的 PPI、某些抗癫痫药也伤骨; 前列腺癌的抗雄激素治疗 (ADT) 掉骨尤其猛, 用的时候必须同步护骨。别的病: 慢性肾病、乳糜泻 (吸收不良), 以及多发性骨髓瘤——如果一个 50 岁以上的人出现说不清来由的骨痛、或轻轻一下就病理性骨折, 医生会特别留神排查骨髓瘤。生活方式: 大量饮酒、抽烟、维生素 D 缺乏。
查出原因之后, 处理跟着改
真查出是某个具体原因, 处理方式会跟着调, 有几处关系到安全, 值得记一下:类固醇引起的骨松 (GIOP): 要趁早上双膦酸盐加钙、维 D, 别等骨密度掉得很低才动手。男性低睾酮加骨松: 可以评估补睾酮 (TRT), 但只是临界、症状又不明确的, 不要轻易上。甲状旁腺亢进: 手术把那个腺瘤切掉后, 骨松常常能自己好转。慢性肾病: 肾功能差到一定程度 (eGFR < 30) 时, 普通双膦酸盐不能用, 一般改用狄诺塞麦 (调整剂量) 或先保守处理。乳糜泻: 严格无麸质饮食加上补回缺的营养, 骨密度往往 1-2 年就能回来。
Chapter 5
Anti-OP drugs
Anti-OP drugs
Pharmacotherapy (high-risk + already-fractured patients):
Indications (ACR / Endocrine Society 2020):
DXA T ≤ -2.5 (any site)Prior fragility fracture + T between -2.5 and -1.0 (osteopenia + fracture)FRAX 10-year hip fracture ≥ 3% or major fracture ≥ 20%
① Bisphosphonates · first-line:
Inhibit osteoclasts → ↓ bone resorption → ↑ BMDAlendronate 70 mg/week: first-line, cheapRisedronate / ibandronateZoledronic acid 5 mg/year IV (Black 2007 NEJM HORIZON): for patients unable to take orally or with poor adherence; vertebral fracture risk ↓ 70%Side effects: esophageal irritation (oral) + rare osteonecrosis of the jaw (ONJ) + atypical femur fracture (AFF) (long-term ≥ 5-year use)Administration: fasting + large glass of water + remain upright 30 minutes (oral)Duration: typically 3-5 years, then a drug holiday of 1-2 years — continue in high-risk patients
Indications (ACR / Endocrine Society 2020):
DXA T ≤ -2.5 (any site)Prior fragility fracture + T between -2.5 and -1.0 (osteopenia + fracture)FRAX 10-year hip fracture ≥ 3% or major fracture ≥ 20%
① Bisphosphonates · first-line:
Inhibit osteoclasts → ↓ bone resorption → ↑ BMDAlendronate 70 mg/week: first-line, cheapRisedronate / ibandronateZoledronic acid 5 mg/year IV (Black 2007 NEJM HORIZON): for patients unable to take orally or with poor adherence; vertebral fracture risk ↓ 70%Side effects: esophageal irritation (oral) + rare osteonecrosis of the jaw (ONJ) + atypical femur fracture (AFF) (long-term ≥ 5-year use)Administration: fasting + large glass of water + remain upright 30 minutes (oral)Duration: typically 3-5 years, then a drug holiday of 1-2 years — continue in high-risk patients
什么时候该上药: 三条线
药物治疗针对高风险和已经骨折的人。下面任何一条满足了, 指南 (ACR / Endocrine Society 2020) 就建议启动:DXA T ≤ -2.5 (任何部位)有过脆性骨折, 且 T 在 -2.5 到 -1.0 之间 (骨量减少加骨折)FRAX 算出的 10 年髋骨折 ≥ 3%, 或主要骨折 ≥ 20%
双膦酸盐: 剂量 · 副作用 · 疗程
品种和剂量:阿仑膦酸 (Alendronate) 70 mg/周: 口服一线, 便宜。同类还有利塞膦酸和伊班膦酸。唑来膦酸 (Zoledronic acid) 5 mg/年 IV (Black 2007 NEJM HORIZON): 给不能口服或依从性差的人; 椎体骨折风险 ↓ 70%。
服用注意: 空腹 + 大杯水 + 站立 30 分钟 (口服), 目的是别让药片停在食道上。
副作用: 口服会刺激食道; 长期 (≥ 5 年) 使用有罕见的颌骨坏死 (ONJ) 和非典型股骨骨折 (AFF)。
疗程: 一般 3-5 年, 之后给 1-2 年的药物假期 — 高风险者继续。
Denosumab + anabolics
② Denosumab · receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone. mAb (Cummings 2009 NEJM FREEDOM):Anti-RANKL mAb → blocks osteoclast differentiation (atlas bone L3 covers RANKL/OPG)60 mg SC every 6 monthsPotent: vertebral fracture ↓ 68%, hip ↓ 40%Critical warning: stopping → rapid BMD loss + rebound multiple vertebral fractures → must bridge with a bisphosphonate, never simply discontinueSuited to patients committed to long-term therapy + unable to take bisphosphonates (CKD etc.)
③ Teriparatide / Abaloparatide (parathyroid hormone: Released when blood calcium dips — it pulls calcium back into the blood from bone, kidney, and gut. analogues):
Stimulate osteoblasts → true bone gain (not just resorption inhibition)SC injection, expensive, for severe osteoporosis + multiple fracturesDuration ≤ 2 years + followed by anti-resorptive (bisphosphonate / denosumab) consolidationContraindicated: prior osteosarcoma / irradiated bone / hypercalcemia
④ Romosozumab (anti-sclerostin mAb):
Dual action: bone formation + resorption inhibition (sclerostin suppresses osteoblasts; blocking it favours formation)Monthly SC × 12 months + follow with a bisphosphonatePotent: greater BMD gain and fracture reduction than bisphosphonates and denosumabCardiovascular warning: ARCH trial showed slightly increased MACE; contraindicated in those with prior CV disease
Hormones / male / long-term
⑤ Estrogen + SERMs:HRT: early perimenopause (initiated at 50-59 + short term), see atlas perimenopause/mht L4Raloxifene (SERM): prevents vertebral fracture, reduces breast cancer, but ↑ VTEBazedoxifene + estrogen
⑥ Male osteoporosis:
Covered in the previous scene. Bisphosphonates + Ca + D + strength training apply equallyIf low T: evaluate TRT (atlas andropause/trt L4, strict indications)
Treatment duration + long-term management:
Re-evaluate at 3-5 yearsDrug holiday + DXA + bone markers (CTX / P1NP)Multidisciplinary: endocrinology / rheumatology / geriatrics / nutrition / physiotherapy
Drug map + self-check + links
Drug-choice summary:| Patient situation | First-line | Alternative |
|---|---|---|
| Postmenopausal OP, no contraindication | Alendronate oral | Risedronate / Zoledronic IV |
| Esophageal issues / poor adherence | Zoledronic annual / Denosumab | — |
| CKD (eGFR < 30) | Denosumab (dose-adjusted) | — |
| Severe OP / multiple vertebral fractures | Teriparatide / Romosozumab → bisphosphonate | Denosumab |
| Cardiovascular disease | Bisphosphonate (avoid Romosozumab) | Denosumab |
| Male osteoporosis | Alendronate / Zoledronic / Denosumab | + TRT if low T |
| Steroid-induced | Risedronate / Zoledronic | + Ca + D fortification |
Self-check:
Height loss > 4 cm (vs young adulthood) = possible vertebral compression fracture, get X-rayKyphosis + chronic back pain: imaging assessmentAny fragility fracture (fracture from minor fall): immediate DXA + work-up
Connections to other atlas islands:
calcium + bone + bone-deposit L4 (mechanism)vitamin-d + vitamin-k2 (D-K-Ca trio)protein + sarcopenia (protein + muscle)exercise + heat-cold-therapy (strength training + hormesis)perimenopause/mht + andropause (hormones)GERD + long-term PPI (absorption impact)
References · 8
- Compston, J. E., McClung, M. R., & Leslie, W. D. (2019). Osteoporosis. The Lancet, 393(10169), 364-376. 10.1016/S0140-6736(18)32112-3
- Wang, L., Yu, W., Yin, X., Cui, L., Tang, S., Jiang, N., et al. (2021). Prevalence of osteoporosis and fracture in China: the China Osteoporosis Prevalence Study. JAMA Network Open, 4(8), e2121106. n=20,416, fieldwork 2017-2018. Aged 40+: osteoporosis in 20.6% of women (95% CI 19.3-22.0) and 5.0% of men (4.2-5.8); vertebral fracture 10.5% of men and 9.7% of women — nearly identical between the sexes. Only 1.4% of women and 0.3% of men with osteoporosis or fracture were on treatment. 10.1001/jamanetworkopen.2021.21106
- Cummings, S. R., San Martin, J., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., et al. (2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine, 361(8), 756-765. 10.1056/NEJMoa0809493
- Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., et al. (2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine, 356(18), 1809-1822. 10.1056/NEJMoa067312
- Fuchs, R. K., Bauer, J. J., & Snow, C. M. (2001). Jumping improves hip and lumbar spine bone mass in prepubescent children: a randomized controlled trial. Journal of Bone and Mineral Research, 16(1), 148-156. ⚠️ POPULATION: 89 PREPUBESCENT CHILDREN aged 5.9-9.8 years, 100 jumps from a 61 cm box, 3×/week for 7 months. It is not a study of women under 50, and the site used to present it as one. 10.1359/jbmr.2001.16.1.148
- Sherrington, C., Michaleff, Z. A., Fairhall, N., Paul, S. S., Tiedemann, A., Whitney, J., et al. (2017). Exercise to prevent falls in older adults: an updated systematic review and meta-analysis. British Journal of Sports Medicine, 51(24), 1750-1758. 99 comparisons from 88 trials, 19,478 participants. ⚠️ THE DOSE IS THE FINDING: exercise overall cut the fall RATE by 21% (RR 0.79, 95% CI 0.73-0.85); programmes that BOTH challenged balance AND ran more than 3 h/week cut it 39% (IRR 0.61, 0.53-0.72), and those two variables explained 76% of the between-trial heterogeneity. No effect was seen in residential care, stroke survivors, or people recently discharged from hospital. 10.1136/bjsports-2016-096547
- Bolland, M. J., Avenell, A., Baron, J. A., Grey, A., MacLennan, G. S., Gamble, G. D., & Reid, I. R. (2010). Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ, 341, c3691. 10.1136/bmj.c3691
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014). Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporosis International, 25(10), 2359-2381. 10.1007/s00198-014-2794-2